FDA consultation on the Use of Data Monitoring Committees in Clinical Trials Guidance for Industry (Catapult’s regulatory round-up – february 2024)

Étiquettes : Clinical trialsDataFDAIndustry

• Article suivant Consultation on Notifying the FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act (Catapult’s regulatory round-up – february 2024)
• Article précédent FDA consultation on Potency Assurance for Cellular and GeneTherapy Products (Catapult’s regulatory round-up – february 2024)

Vous aimerez aussi...

• 0

  Public consultation on Human Gene Therapy Products incorporating Human Genome Editing Food and Drug Administration (FDA) (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022)

  03/08/2022

   par adelage

   par adelage · Published 03/08/2022 · Last modified 23/08/2022

• 0

  FDA Technologies Designation Program (from Catapult’s regulatory round-up – December 2023)

  07/08/2024

   par adelage

   par adelage · Published 07/08/2024

• 0

  USA FDA – Public consultation on Draft guidance (Catapult’s regulatory round-up – June)

  21/02/2024

   par adelage

   par adelage · Published 21/02/2024